Mirapex ER (Pramipexole) Oral: Uses, Side Effects, Dosage – Verywell Health

Related Articles:

• Mirapex: A Miracle Treatment with Troubling Effects for Some August 18, 2017 Mirapex (pramipexole), a common treatment for Parkinson’s disease, is believed to work by boosting the action of whatever dopamine is available, which is low in people with Parkinson’s. It is a dopamine agonist that directly stimulates nerves in the brain that are not naturally being stimulated by dopamine. Several years ago, my doctor diagnosed me with Parkinson’s. Immediately, he placed me on…
• Mirapex Sustained Release Tablet Outperforms Immediate Release Version to Relieve Sleep Disturbances July 12, 2018 Sustained release formulation of pramipexole (Mirapex, Boehringer Ingelheim) outperforms its immediate release alternative to treat sleep disturbances in advanced Parkinson’s patients, a new study suggests. The research, “Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations,” was published in Drug Design, Development and Therapy. Sleep disturbances, which may include insomnia, nightmares, restless sleep and…
• Pharma Two B Doses First Patients in Early-stage Parkinson’s Phase 3 Trial February 12, 2018 Israel’s Pharma Two B has dosed the first patients in a Phase 3 trial to evaluate the safety and efficacy of its drug candidate P2B001 to treat early-stage Parkinson’s disease. P2B001 combines low-dose pramipexole and rasagiline, sold under the brand names Mirapex and Azilect. This new approach takes advantage of the well-known therapeutic effects and good safety profile of both Parkinson’s…
• Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease April 25, 2022 J Healthc Eng. 2022 Apr 13;2022:7002630. doi: 10.1155/2022/7002630. eCollection 2022.ABSTRACTTo explore the inhibition of pramipexole on the neuronal apoptosis and its influences on the expressions of brain tissue brain-derived neurotrophic factor (BDNF), and serum miR-103a and miR-30b and inflammatory factors in rats with Parkinson's disease. A total of 36 Sprague-Dawley rats were randomly divided into normal group (n = 12),…
• Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease April 25, 2022 J Healthc Eng. 2022 Apr 13;2022:7002630. doi: 10.1155/2022/7002630. eCollection 2022.ABSTRACTTo explore the inhibition of pramipexole on the neuronal apoptosis and its influences on the expressions of brain tissue brain-derived neurotrophic factor (BDNF), and serum miR-103a and miR-30b and inflammatory factors in rats with Parkinson's disease. A total of 36 Sprague-Dawley rats were randomly divided into normal group (n = 12),…
• Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease April 25, 2022 J Healthc Eng. 2022 Apr 13;2022:7002630. doi: 10.1155/2022/7002630. eCollection 2022.ABSTRACTTo explore the inhibition of pramipexole on the neuronal apoptosis and its influences on the expressions of brain tissue brain-derived neurotrophic factor (BDNF), and serum miR-103a and miR-30b and inflammatory factors in rats with Parkinson's disease. A total of 36 Sprague-Dawley rats were randomly divided into normal group (n = 12),…
• Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease April 25, 2022 J Healthc Eng. 2022 Apr 13;2022:7002630. doi: 10.1155/2022/7002630. eCollection 2022.ABSTRACTTo explore the inhibition of pramipexole on the neuronal apoptosis and its influences on the expressions of brain tissue brain-derived neurotrophic factor (BDNF), and serum miR-103a and miR-30b and inflammatory factors in rats with Parkinson's disease. A total of 36 Sprague-Dawley rats were randomly divided into normal group (n = 12),…
• Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
• Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
• Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. June 27, 2019 Related ArticlesPramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Jun 24;: Authors: Andrabi SS, Ali M, Tabassum H, Parveen S, Parvez S Abstract Dopamine D2 receptor agonist, pramipexole, has been found to elicit neuroprotection in patients with Parkinson disease (PD) and restless leg syndrome. Recent evidence has shown that pramipexole mediates its neuroprotection…
• Certain Impulse-Control Medications May Not Work for Parkinson’s Disease, Study Suggests January 10, 2020 Medications used to manage impulse control disorders may not help Parkinson’s disease patients taking Mirapex (pramipexole) and Requip (ropinirole), and may even worsen their episodes, according to new research. The study, titled “What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson’s disease? A preliminary pharmacoepidemiologic study,” was published in the journal PLoS One. Mirapex and Requip are dopamine…
• Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction:  Parkinson’s changes us in many ways: it makes us stronger by…
• Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction:  Parkinson’s changes us in many ways: it makes us stronger by…
• Delays in Parkinson’s Treatment Due to Fear of Side Effects a Serious Problem, Neurologist Says April 4, 2019 A fear of the potential side effects of Parkinson’s disease treatments, dubbed “levodopa phobia,” can cause patients and their doctors to delay the use of these therapies, a neurologist says. However, evidence suggests that starting adequate levodopa therapy early is safe, particularly for patients with increased functional disability, according to a lecture by Joseph Jankovic, MD, a professor of neurology…
• Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study March 25, 2021 Parkinsons Dis. 2021 Mar 3;2021:8834950. doi: 10.1155/2021/8834950. eCollection 2021.ABSTRACTOBJECTIVE: To explore the efficacy and safety of pramipexole sustained release (SR) versus pramipexole immediate release (IR) in treating nocturnal symptoms in levodopa-treated Chinese patients with advanced Parkinson's disease (PD) and sleep disturbances.METHOD: SUSTAIN was an open-label, randomised, active-controlled parallel group exploratory pilot study (NCT03521635). A total of 98 patients were randomly…
• Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study March 25, 2021 Parkinsons Dis. 2021 Mar 3;2021:8834950. doi: 10.1155/2021/8834950. eCollection 2021.ABSTRACTOBJECTIVE: To explore the efficacy and safety of pramipexole sustained release (SR) versus pramipexole immediate release (IR) in treating nocturnal symptoms in levodopa-treated Chinese patients with advanced Parkinson's disease (PD) and sleep disturbances.METHOD: SUSTAIN was an open-label, randomised, active-controlled parallel group exploratory pilot study (NCT03521635). A total of 98 patients were randomly…
• Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study March 25, 2021 Parkinsons Dis. 2021 Mar 3;2021:8834950. doi: 10.1155/2021/8834950. eCollection 2021.ABSTRACTOBJECTIVE: To explore the efficacy and safety of pramipexole sustained release (SR) versus pramipexole immediate release (IR) in treating nocturnal symptoms in levodopa-treated Chinese patients with advanced Parkinson's disease (PD) and sleep disturbances.METHOD: SUSTAIN was an open-label, randomised, active-controlled parallel group exploratory pilot study (NCT03521635). A total of 98 patients were randomly…
• Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study March 25, 2021 Parkinsons Dis. 2021 Mar 3;2021:8834950. doi: 10.1155/2021/8834950. eCollection 2021.ABSTRACTOBJECTIVE: To explore the efficacy and safety of pramipexole sustained release (SR) versus pramipexole immediate release (IR) in treating nocturnal symptoms in levodopa-treated Chinese patients with advanced Parkinson's disease (PD) and sleep disturbances.METHOD: SUSTAIN was an open-label, randomised, active-controlled parallel group exploratory pilot study (NCT03521635). A total of 98 patients were randomly…
• Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study March 25, 2021 Parkinsons Dis. 2021 Mar 3;2021:8834950. doi: 10.1155/2021/8834950. eCollection 2021.ABSTRACTOBJECTIVE: To explore the efficacy and safety of pramipexole sustained release (SR) versus pramipexole immediate release (IR) in treating nocturnal symptoms in levodopa-treated Chinese patients with advanced Parkinson's disease (PD) and sleep disturbances.METHOD: SUSTAIN was an open-label, randomised, active-controlled parallel group exploratory pilot study (NCT03521635). A total of 98 patients were randomly…
• Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study March 25, 2021 Parkinsons Dis. 2021 Mar 3;2021:8834950. doi: 10.1155/2021/8834950. eCollection 2021.ABSTRACTOBJECTIVE: To explore the efficacy and safety of pramipexole sustained release (SR) versus pramipexole immediate release (IR) in treating nocturnal symptoms in levodopa-treated Chinese patients with advanced Parkinson's disease (PD) and sleep disturbances.METHOD: SUSTAIN was an open-label, randomised, active-controlled parallel group exploratory pilot study (NCT03521635). A total of 98 patients were randomly…
• Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study March 25, 2021 Parkinsons Dis. 2021 Mar 3;2021:8834950. doi: 10.1155/2021/8834950. eCollection 2021.ABSTRACTOBJECTIVE: To explore the efficacy and safety of pramipexole sustained release (SR) versus pramipexole immediate release (IR) in treating nocturnal symptoms in levodopa-treated Chinese patients with advanced Parkinson's disease (PD) and sleep disturbances.METHOD: SUSTAIN was an open-label, randomised, active-controlled parallel group exploratory pilot study (NCT03521635). A total of 98 patients were randomly…
• Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease February 3, 2022 Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039.ABSTRACTBACKGROUND AND PURPOSE: Parkinson's disease is a progressive neurodegenerative disease characterized by motor and non-motor symptoms. Levodopa is the most effective drug in the symptomatic treatment of the disease. Dopamine receptor agonists provide sustained dopamin-ergic stimulation and have been found to delay the initiation of levodopa treatment and reduce the frequency of various motor…